Your browser doesn't support javascript.
loading
Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2-Naive Residents of Nursing Homes.
Pannus, Pieter; Neven, Kristof Y; De Craeye, Stéphane; Heyndrickx, Leo; Vande Kerckhove, Sara; Georges, Daphnée; Michiels, Johan; Francotte, Antoine; Van Den Bulcke, Marc; Zrein, Maan; Van Gucht, Steven; Schmickler, Marie Noëlle; Verbrugghe, Mathieu; Matagne, André; Thomas, Isabelle; Dierick, Katelijne; Weiner, Joshua A; Ackerman, Margaret E; Goriely, Stanislas; Goossens, Maria E; Ariën, Kevin K; Desombere, Isabelle; Marchant, Arnaud.
Afiliación
  • Pannus P; SD Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
  • Neven KY; SD Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
  • De Craeye S; SD Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
  • Heyndrickx L; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
  • Vande Kerckhove S; SD Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
  • Georges D; Institute for Medical Immunology and ULB Center for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium.
  • Michiels J; Laboratory of Enzymology and Protein Folding, Centre for Protein Engineering, InBioS, University of Liège, Liège, Belgium.
  • Francotte A; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
  • Van Den Bulcke M; SD Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
  • Zrein M; SD Epidemiology and Public Health, Sciensano, Brussels, Belgium.
  • Van Gucht S; InfYnity Biomarkers, Lyon, France.
  • Schmickler MN; SD Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
  • Verbrugghe M; Mensura EDPB, Occupational Health Service, Antwerp, Belgium.
  • Matagne A; Mensura EDPB, Occupational Health Service, Antwerp, Belgium.
  • Thomas I; Laboratory of Enzymology and Protein Folding, Centre for Protein Engineering, InBioS, University of Liège, Liège, Belgium.
  • Dierick K; SD Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
  • Weiner JA; SD Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
  • Ackerman ME; Thayer School of Engineering, Dartmouth College, Hanover, NH, USA.
  • Goriely S; Thayer School of Engineering, Dartmouth College, Hanover, NH, USA.
  • Goossens ME; Institute for Medical Immunology and ULB Center for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium.
  • Ariën KK; SD Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
  • Desombere I; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
  • Marchant A; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
Clin Infect Dis ; 75(1): e695-e704, 2022 08 24.
Article en En | MEDLINE | ID: mdl-34864935
BACKGROUND: Residents of nursing homes (NHs) are at high risk of coronavirus disease 2019 (COVID-19)-related disease and death and may respond poorly to vaccination because of old age and frequent comorbid conditions. METHODS: Seventy-eight residents and 106 staff members, naive to infection or previously infected with severe acute respiratory syndrome coronavirus (SARS-CoV-2), were recruited in NHs in Belgium before immunization with 2 doses of 30 µg BNT162b2 messenger RNA (mRNA) vaccine at days 0 and 21. Binding antibodies (Abs) to SARS-CoV-2 receptor-binding domain (RBD), spike domains S1 and S2, RBD Ab avidity, and neutralizing Abs against SARS-CoV-2 wild type and B.1.351 were assessed at days 0, 21, 28, and 49. RESULTS: SARS-CoV-2-naive residents had lower Ab responses to BNT162b2 mRNA vaccination than naive staff. These poor responses involved lower levels of immunoglobulin (Ig) G to all spike domains, lower avidity of RBD IgG, and lower levels of Abs neutralizing the vaccine strain. No naive residents had detectable neutralizing Abs to the B.1.351 variant. In contrast, SARS-CoV-2-infected residents had high responses to mRNA vaccination, with Ab levels comparable to those in infected staff. Cluster analysis revealed that poor vaccine responders included not only naive residents but also naive staff, emphasizing the heterogeneity of responses to mRNA vaccination in the general population. CONCLUSIONS: The poor Ab responses to mRNA vaccination observed in infection-naive NH residents and in some naive staff members suggest suboptimal protection against breakthrough infection, especially with variants of concern. These data support the administration of a third dose of mRNA vaccine to further improve protection of NH residents against COVID-19.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas Virales / COVID-19 Límite: Humans Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2022 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas Virales / COVID-19 Límite: Humans Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2022 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Estados Unidos